Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: An evidence-based review

Core Evidence

Volumn 6, Issue , 2011, Pages 59-66

  Kirkby, Stephen ^a   Novak, Kimberly ^a   McCoy, Karen ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Aztreonam lysine; Cystic fibrosis; Inhaled antibiotics; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM LYSINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENTAMICIN; PLACEBO; TOBRAMYCIN;

BACTERIAL COLONIZATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY FAILURE; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG INFECTION; PATHOGENESIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW;

EID: 84876264905     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S11181     Document Type: Review

References (40)

1. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006;173(5):475-482.
2. Cystic Fibrosis Foundation Patient Registry. 2009 Annual Data Report. Bethesda MD: ©2011 Cystic Fibrosis Foundation. http://www.cff.org/ UploadedFiles/research/ClinicalResearch/Patient-Registry-Report-2009.pdf.
3. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918-951.
4. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100.
5. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32(5):356-366.
6. Kirkby S, Novak K, McCoy K. Update on antibiotics for infection control in cystic fibrosis. Expert Rev Anti Infect Ther. 2009;7(8):967-980.
7. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808.
8. Gibson RL, Retsch-Bogart GZ, Oermann C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2006;41(7):656-665.
9. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992-2001.
10. Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet. 1995;29:777-807.
11. Cystic fibrosis mutation database. Available at: http://www.genet. sickkids.on.ca/StatisticsPage.html. Last updated April 25, 2011. Accessed July 8, 2011.
12. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005;293(5):581-588.
13. Kuhn RJ. Formulation of aerosolized therapeutics. Chest. 2001;120 (Suppl 3):94S-98S.
14. Toso C, Williams DM, Noone PG. Inhaled antibiotics in cystic fibrosis: a review. Ann Pharmacother. 1996;30(7-8):840-850.
15. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340(1):23-30.
16. LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest. 2001;120(Suppl 3):118S-123S.
17. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev. 2011;(3):CD001021.
18. Reed MD, Aronoff SC, Stern RC, et al. Single-dose pharmacokinetics of aztreonam in children with cystic fibrosis. Pediatr Pulmonol. 1986;2(5):282-286.
19. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20(3):658-664.
20. McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med. 2007;357(22):2310-2311.
21. Schaad UB, Wedgwood-Krucko J, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr. 1987;111(4):599-605.
22. Kirkby S, Astor T, Patel A, Novak K, McCoy K. Treatment of mycobacterium abscessus lung disease: A single center experience. Am J Respir Crit Care Med. 2009;179(1):A4085.
23. Sykes RB, Bonner DP, Bush K, Georgopapadakou NH. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic Gram-negative bacteria. Antimicrob Agents Chemother. 1982;21(1):85-92.
24. Brewer NS, Hellinger WC. The monobactams. Mayo Clin Proc. 1991;66(11):1152-1157.
25. Bechard DL, Hawkins SS, Dhruv R, Friedhoff LT. Penetration of aztreonam into human bronchial secretions. Antimicrob Agents Chemother. 1985;27(2):263-264.
26. Aronoff SC, Klinger JD. In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis. Antimicrob Agents Chemother. 1984;25(2):279-280.
27. Bosso JA, Black PG, Matsen JM. Efficacy of aztreonam in pulmonary exacerbations of cystic f ibrosis. Pediatr Infect Dis J. 1987;6(4):393-397.
28. Bosso JA, Black PG. Controlled trial of aztreonam vs tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J. 1988;7(3):171-176.
29. Dietzsch HJ, Gottschalk B, Heyne K, Leupoid W, Wunderlich P. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics. 1975;55(1):96-100.
30. Sapienza MA, Kharitonov SA, Horvath I, Chung KF, Barnes PJ. Effect of inhaled L-arginine on exhaled nitric oxide in normal and asthmatic subjects. Thorax. 1998;53(3):172-175.
31. Grasemann H, Kurtz F, Ratjen F. Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med. 2006;174(2):208-212.
32. Retsch-Bogart GZ, Burns JL, Otto KL, et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol. 2008;43(1):47-58.
33. Azactam® package insert. Princeton, NJ: Bristol-Myers Squibb, January 2010.
34. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921-928.
35. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135(5):1223-1232.
36. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 2010;45(11):1121-1134.
37. Wainwright CE, Quittner AL, Geller DE, et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros. 2011;10(4):234-242.
38. De Boeck K, Malfroot A, Van Schil L, et al. Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients. Eur Respir J. 2004;23(6):851-856.
39. Courtney JM, Dunbar KE, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros. 2004;3(2):93-98.
40. US Food and Drug Administration. FDA Labeling information- Cayston. FDA Website [online]. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2010/0508141bl.pdf.